Conspectus Nuclear medicine leverages radioisotopes of a wide range of elements, a
significant portion of which are metals, for the diagnosis and treatment of disease. To …

The validation of prostate specific membrane antigen (PSMA) as a molecular target in
metastatic castration-resistant prostate cancer has stimulated the development of multiple …

Superior bifunctional chelating ligands, which can sequester both α-emitting radionuclides
(225Ac, 213Bi) and their diagnostic companions (155Tb, 111In), remain a formidable …

We report a nonadentate bispidine (3, 7-diazabicyclo [3.3. 1] nonane) that unveils the
potential to bind theranostically relevant radionuclides, including indium-111, lutetium-177 …

Actinium-225 (225Ac) is one of the most promising radionuclides for targeted alpha therapy
(TAT). With a half-life of 9.92 days and a decay chain that emits four high-energy α particles …

The widespread use of peptide receptor radionuclide therapy (PRRT) represents a major
therapeutic breakthrough in nuclear medicine, particularly since the introduction of 177Lu …

Octadentate and specifically nonadentate ligands with a bispidine scaffold (3, 7-diazabicyclo
[3.3. 1] nonane) are known to be efficiently coordinated to a range of metal ions of interest in …

Radioisotopes of metallic elements, or radiometals, are widely employed in both therapeutic
and diagnostic nuclear medicine. For this application, chelators that efficiently bind the …

Conspectus Nuclear medicine harnesses radioisotopes for the diagnosis and treatment of
disease. While the isotopes 99mTc and 111In have enabled the clinical diagnosis of millions …

We report a detailed investigation on the use of chelators PYTAM, H4PYTAMGly, CHX-
PYTAM and H4CHX-PYTAMGly for the complexation of Pb (II)-radioisotopes with potential …